Thymosin in the treatment of HBeAG-negative chronic hepatitis B

Medical Science Monitor

Volumn 9, Issue 8, 2003, Pages

  Saruc, Murat ^a,b   Ozden, Nuri ^a   Yuceyar, Hakan ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis B; HBeAg negative; Interferon; Therapy; Thymosin

Indexed keywords

ALPHA2 INTERFERON; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; THYMOSIN ALPHA1; VIRUS DNA;

CHRONIC HEPATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; RELAPSE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

2-AMINOPURINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; THYMOSIN;

EID: 0141706984     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Alexander GJ, Williams R: Natural history and therapy of chronic hepatitis B virus infection. Am J Med, 1988; 85: 143-146
2. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology, 2001; 34: 1225-1241
3. Andreone P, Biselli M, Gramenzi A et al: Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation, 2002; 74: 1119-1124
4. Daikoku M, Nakata K, Nagataki S et al: [Association of precore mutant HBV with HBe-seroconversion]. Nippon Rinsho, 1995; 53 Suppl: 201-204
5. Suzuki F, Suzuki Y, Tsubota A et al: Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol, 2002; 37: 824-830
6. Chu CM: Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection. Am J Gastroenterol, 2002; 97: 2138-2139; discussion 2139-2140
7. Knoll A, Rohrhofer A, Kochanowski B et al: Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol, 1999; 59: 14-18
8. Lok AS, Hussain M, Cursano C et al: Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology, 2000; 32; 1145-1153
9. Laras A, Koskinas J, Avgidis K et al: Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat, 1998; 5: 241-248
10. Hunt CM, McGill JM, Allen MI et al: Clinical relevance of hepatitis B viral mutations. Hepatology, 2000; 31: 1037-1044
11. Brunetto MR, Oliveri F, Coco B et al: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol, 2002; 36: 263-270
12. Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 2001; 34: 617-624
13. Hoofnagle JH: Therapy of viral hepatitis. Digestion, 1998; 59: 563-578
14. Manesis EK, Hadziyamis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001; 121: 101-109
15. Fattovich G, Farci P, Rugge M et al: A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology, 1992; 15: 584-589
16. Alberti A, Brunetto MR, Colombo M et al: Recent progress and new trends in the treatment of hepatitis B. J Med Virol, 2002; 67: 458-462
17. Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000: summary of a workshop. Gastroenterology, 2001; 120: 1828-1853
18. Oliveri F, Santantonio T, Bellati G et al: Long term response to therapy of chronic anti-HBc-positive hepatitis B is peor independent of type and schedule of interferon. Am J Gastroenterol, 1999; 94: 1366-1372
19. Papatheodoridis GV, Manesis E, Hadziyamtis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol, 2001; 34: 306-313
20. Tamlli I, Francavilla R, Rizzo GL et al: Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol, 2001; 35: 805-810
21. Wong JB, Koff RS, Tine F et al: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med, 1995; 122: 664-675
22. Cho SW, Hahm KB, Kim JH: Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology, 2000; 32: 1163-1169
23. Lai CL, Chien RN, Leung NW et al: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998; 339: 61-68
24. Liaw YF: Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol, 1997; 12: S346-353
25. Hong JH, Choi Y, Chun BK et al: Current status of anti-HBV chemotherapy. Arch Pharm Res, 1998; 21: 89-105
26. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 2000; 32: 847-851
27. Santantonio T, Mazzola M, Iacovazzi T et al: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol, 2000; 32: 300-306
28. Tassopoulos NC, Volpes R, Pastore G et al: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology, 1999; 29: 889-896
29. Allen MI, Deslauriers M, Andrews CW et al: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 1998; 27: 1670-1677
30. Malik AH, Lee WM: Hepatitis B therapy: the plot thickens. Hepatology, 1999; 30: 579-581
31. Ben-Ari Z, Zemel R, Kazetsker A et al: Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Am J Gastroenterol, 1999; 94: 663-667
32. Papatheodoridis GV, Dimou E, Laras A et al: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology, 2002; 36: 219-226
33. Dienstag JL, Schiff ER, Wright TL et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 1999; 341: 1256-1263
34. Schalm SW, Heathcote J, Cianciara J et al: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000; 46: 562-568
35. Schiff E, Karayalcin S, Grinnu I et al: A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology, 1998; 28: 388A
36. Lau GK, Tsiang M, Hou J et al: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology, 2000; 32: 394-399
37. Di Bisceglie AM: Combination therapy for hepatitis B. Gut, 2002; 50: 443-445
38. Mutchnick MG, Ehrinpreis MN, Kinzie JL, et al: Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res, 1994; 24: 245-257
39. Sztein MB, Goldstein AL: Thymic hormones: a clinical update. Springer Semin Immunopathol, 1986; 9: 1-18
40. Zhuang L, You J, Tang BZ et al: Preliminary results of Thymosin-α1 versus interferon-alpha-treatmeat in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol, 2001; 7: 407-410
41. Lau GK: Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol, 2000; 15 Suppl: E46-52
42. Oates KK, Goldstein AL: Thymosin. In: DeVita VT, Hellman S, Rosenberg SA (eds.): Biological therapy of cancer. J.B. Lippincott, Philadelphia pp. 841-852
43. Mutchnick MG, Appelman HD, Chung HT et al: Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology, 1991; 14: 409-415
44. Mutchnick MG, Lindsay KL, Schiff ER et al: Thymosin alpha 1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat, 1999; 6: 397-403
45. Chan HL, Tang JL, Tam W et al: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther, 2001; 15: 1899-1905
46. Saruc M, Yuceyar H, Kucukmetin N et al: Combination thymosin-α1 and interferon-α2b in the treatment of anti-IIBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology, 2002; 49: 798-802